Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01183559 · ClinicalTrials.gov registry record · Phase 1
A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery
A Phase 1 study, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01183559 is a Phase 1 study that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 9 participants.
The verdict
NCT01183559, a Phase 1 study, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the most tolerable and safe dose of ZD6474 (Zactima, Vandetanib) when given with standard chemotherapy, radiation therapy and surgery in patients with cancer of the esophagus
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Vandetanib
- DRUG 5 Fluorouracil (FU)
- RADIATION External Beam Radiation Therapy (RT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-08-07 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01183559
The ClinicalTrials.gov registry entry for NCT01183559 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT01183559 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01183559 about?
NCT01183559 is a clinical study titled "A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery". The purpose of the study is to determine the most tolerable and safe dose of ZD6474 (Zactima, Vandetanib) when given with standard chemotherapy, radiation therapy and surgery in patients with cancer of the esophagus
What is the current status of trial NCT01183559?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2008-08-07. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01183559?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Vandetanib (DRUG), 5 Fluorouracil (FU) (DRUG), External Beam Radiation Therapy (RT) (RADIATION).
Who is sponsoring clinical trial NCT01183559?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.